StockData
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd (TLX) stock

TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 20, 2026Score 3/30
$8.96+0.11 (+1.19%)

Close on Nov 18, 2026Market cap $3.04BP/E –Yield –

Telix Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was $29.78M, down 46.0% from the year before.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$29.78M-46.0%
FY2024Dec 31, 2024$55.18M+401.2%
FY2023Dec 31, 2023$11.01M–

More Telix Pharmaceuticals figures

See a number that looks wrong?